Tissue-specific mutant frequencies and mutational spectra in cyclophosphamide-treated lacl transgenic mice

Environmental and Molecular Mutagenesis

Volumn 34, Issue 2-3, 1999, Pages 154-166

  Gorelick, Nancy J ^a   Andrews, Julie L ^a,f   DeBoer, Johan G ^b   Young, Robert ^c   Gibson, David P ^a   Walker, Vernon E ^d,e  

^a PROCTER AND GAMBLE COMPANY   (United States)

^b UNIVERSITY OF VICTORIA   (Canada)

^c MA BioServices Inc   (United States)

^d UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^e WADSWORTH CENTER   (United States)

^f NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Cyclophosphamide; lacl; Mutagenesis; Transgenic mice

Indexed keywords

CYCLOPHOSPHAMIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARCINOGENESIS; CARCINOGENICITY; CONTROLLED STUDY; GENE LOCUS; GENOTOXICITY; MALE; MOUSE; MUTAGEN TESTING; MUTATION; MUTATION RATE; NONHUMAN; NUCLEIC ACID BASE SUBSTITUTION; SEQUENCE ANALYSIS; SISTER CHROMATID EXCHANGE; TRANSGENIC MOUSE;

ANIMALS; BACTERIAL PROTEINS; BASE SEQUENCE; BONE MARROW; CYCLOPHOSPHAMIDE; DNA; ESCHERICHIA COLI PROTEINS; KIDNEY; LIVER; MALE; MICE; MICE, TRANSGENIC; MICRONUCLEUS TESTS; MUTAGENS; MUTATION; REPRESSOR PROTEINS; URINARY BLADDER;

EID: 0032698083     PISSN: 08936692     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1098-2280(1999)34:2/3<154::AID-EM15>3.0.CO;2-0     Document Type: Article

References (67)

1. Aidoo A, Lyn-Cook LE, Mittelstaedt RA, Heflich RH, Casciano DA. 1993. The effect of time after treatment, treatment schedule and animal age on the frequency of 6-thioguanine-resistant T-lymphocytes induced in Fischer 344 rats by N-ethyl-N-nitrosourea. Mutat Res 298:169-178.
2. Anderson D, Bishop JB, Garner RC, Ostrosky-Wegman P, Selby PB. 1995. Cyclophosphamide: Review of its mutagenicity for an assessment of potential germ cell risks. Mutat Res 330:115-181.
3. Ashby J, Short JM, Jones NJ, Lefevre PA, Provost GS, Rogers BJ, Martin EA, Parry JM, Burnette K, Glickman BW, Tinwell H. 1994. Mutagenicity of o-anisidine to the bladder of lacI-transgenic B6C3F1 mice: absence of 14C or 32P bladder DNA adduction. Carcinogenesis 15:2291-2296.
4. 4 hot-spot of Salmonella typhimuirum hisD3052 carried on an M13 vector. J Biol Chem 267:22392-22400.
5. Boddy AV, Furtun Y, Sardas S, Sardas O, Idle JR. 1992. Individual variation in the activation and inactivation of metabolic pathways of cyclophosphamide. J Natl Cancer Inst 84:1744-1748.
6. Butterworth BE, Conolly RB, Morgan KT. 1995. A strategy for establishing mode of action of chemical carcinogens as a guide for approaches to risk assessments. Cancer Lett 93:129-146.
7. Carr GJ, Gorelick NJ. 1994. Statistical tests of significance in transgenic assays: considerations on the experimental unit. Environ Mol Mutagen 24:276-282.
8. Carr GJ, Gorelick NJ. 1995. Statistical design and analysis of mutation studies in transgenic mice. Environ Mol Mutagen 25:246-255.
9. Carr GJ, Gorelick NJ. 1996. Mutational spectra in transgenic animal research: Data analysis and study design based upon the mutant frequency. Environ Mol Mutagen 28:405-413.
10. Chenna A, Rieger RA, Iden CR. 1992. Characterization of thymidine adducts fromed by acrolein and 2-bromoacrolein. Carcinogenesis 13:2361-2365.
11. 2-propanodeoxyguanosine adducts in DNA upon reaction with acrolein or crotonaldehyde. Cancer Res 44:990-995.
12. Cochrane JE, Skopek TR. 1994. Mutagenicity of butadiene and its epoxide metabolites: II. Mutational spectra of butadiene, 1,2-epoxybutene and diepoxybutane at the hprt locus in splenic T cells from exposed B6C3F1 mice. Carcinogenesis 15:719-723.
13. Collaborative Study Group for the Micronucleus Test (CSGMT) of the Mammalian Mutagenesis Study subgroup of the Environmental Mutagen Society of Japan (JEMS-MMS). 1992. Micronucleus test with rodent peripheral blood reticulocytes by acridine orange supravital staining. Mutat Res 278:2/3.
14. CSGTM (Collaborative Study Group on the Transgenic Mutation Assay). 1996. Organ variation in the mutagenicity of ethylnitrosourea in Muta™Mouse: Results of the collaborative study on the transgenic mutation assay by IEMS/MMS. Environ Mol Mutagen 28:363-375.
15. Davies R, Oreffo V, Bayliss S, Dinh PA, Lilley KS, White INH, Smith LL, Styles JA. 1996a. Mutational spectra of tamoxifen-induced mutations in the livers of lacI transgenic rats. Environ Mol Mutagen 28:430-433.
16. Davies R, Oreffo V, Martin EA, Lilley KS, Dinh PA, Bayliss S, Edwards RE, Carthew P, White INH, Smith LL, Styles JA. 1996b. Tamoxifen causes gene mutations, DNA adducts and hyperplasia in the livers of Big Blue® transgenic F344 rats. Environ Mol Mutagen 27(Suppl. 27): 16.
17. Davis CD, Dacquel EJ, Schut HAJ, Thorgeirsson SS, Snyderwine EG. 1996. In vivo mutagenicity and DNA adduct levels of heterocyclic amines in MutaMice and c-myc/lacZ double transgenic mice. Mutat Res 356:287-296.
18. de Boer JG, Mirsalis JC, Provost GS, Tindall KR, Glickman, BW. 1996. Spectrum of mutations in kidney, stomach and liver from lad transgenic mice recovered after treatment with tris(2,3-dibromopropyl)phosphate. Environ Mol Mutagen 28:418-423.
19. de Boer JG, Erfle H, Walsh D, Holcroft J, Provost GS, Rogers B, Tindall KR, Glickman BW. 1997. Spectrum of spontaneous mutations in liver tissue of lacI transgenic mice. Environ Mol Mutagen 30:273-286.
20. de Boer JG, Provost GS, Gorelick NJ, Tindall K, Glickman BW. 1998. Spontaneous mutation in lad transgenic mice: a comparison of tissues. Mutagenesis 13:109-114.
21. Douglas GR, Jiao J, Gingerich JD, Soper LM, Gossen JA. 1996. Temporal and molecular characteristics of lacZ mutations in somatic tissues of transgenic mice. Environ Mol Mutagen 28:317-324.
22. Dycaico MJ, Provost GS, Kretz PL, Ransom SL, Moores JC, Short JM. 1994. The use of shuttle vectors for mutation analysis in transgenic mice and rats. Mutat Res 307:461-478.
23. Farabaugh PJ. 1978. Sequence of the lacl gene. Nature 274:765-769.
24. Gorelick NJ. 1995. Overview of mutation assays in transgenic mice for routine testing. Environ Mol Mutagen 25:218-230.
25. Gorelick NJ, Mirsalis JC. 1996. A strategy for the application of transgenic mutagenesis assays. Environ Mol Mutagen 28:434-442.
26. Gorelick NJ, Andrews JL, Gu M, Glickman BW. 1995. Mutational spectra in the lacI gene in skin from 7,12-dimethylbenz[a]anthracene-treated and untreated transgenic mice. Mol Carcinog 14:53-62.
27. Hatanaka Y, Kitagawa Y, Toyoda Y, Kawata T, Ando N, Kawabata Y, Iwai M, Arimura H. 1992. Micronucleus test with cyclophosphamide using mouse peripheral blood reticulocytes. Mutat Res 278: 99-101.
28. Hayashi M, Morita T, Kodama Y, Sofuni T, Ishidate M Jr. 1990. The micronucleus assay with mouse perpheral blood reticulocytes by acridine orange-coated slides. Mutat Res 245:245-249.
29. Hayward JJ, Shane BS, Tindall KR, Cunningham ML. 1995. Differential in vivo mutagenicity of the carcinogen/non-carcinogen pairs 2,4-and 2,6-diaminotoluene. Carcinogenesis 16:2429-2433.
30. Hong PS, Chan KK. 1991. Enzymatic detoxification of phosphoramide mustard by soluble fractions from rat organ tissues. Drug Metab Dispos 19:568-573.
31. Hoorn AJW, Custer LL, Myhr BC, Brusick D, Gossen J, Vijg J. 1993. Detection of chemical mutagens using MutaMouse: a transgenic model. Mutagenesis 8:7-10.
32. Hoyes KP, Wadeson PJ, Sharma HL, Hendry JH. Morris ID. 1998. Mutation studies in lacI transgenic mice after exposure to radiation or cyclophosphamide. Mutagenesis 13:607-612.
33. IARC (International Agency for Research on Cancer). 1981. Monographs on the Evaluation of the Carcinogenic Risk of Chemicals to Humans, vol 26: Some anti-neoplastic and immunosuppressive agents. Lyon: IARC, pp 165-202.
34. Kanekal S, Fraiser L. Kehrer JP. 1992. Pharmacokinetics, metabolic activation, and lung toxicity of cyclophosphamide in C57/B16 and ICR mice. Toxicol Appl Pharmacol 114:1-8.
35. Kastenbaum MA, Bowman KO. 1970. Tables for determining the statistical significance of mutation frequencies. Mutat Res 9:527-549.
36. Kohler SW, Provost GS, Fieck A, Kretz PL, Bullock WO, Sorge JA, Putman DL, Short JM. 1991. Spectra of spontaneous and mutagen-induced mutations in the lacl gene in transgenic mice. Proc Natl Acad Sci U S A 88:7958-7962.
37. Leach EG, Narayanan L, Havre PA, Gunther EJ, Yeasky TM, Glazer PM. 1996. Tissue specificity of spontaneous point mutations in λsupF transgenic mice. Environ Mol Mutagen 28:459-464.
38. Lin SW, Chen JC, Hsu LC, Hsieh C-L, Yoshida A. 1996. Human γ-aminobutyraldehyde dehydrogenase (ALDH9): cDNA sequence, genomic organization, polymorphism, chromosomal localization and tissue expression. Genomics 34:376-380.
39. Meng Q, Recio L, Reilly AA, Wong B, Bauer M, Walker VE. 1998. Species comparison of the mutagenic potency of 1,3-butadiene at the hprt locus of T-lymphocytes following inhalation exposure of female B6C3F1 mice and F344 rats. Carcinogenesis 19:1019-1027.
40. Meng Q, Singh NK, Heflich RH, Walker VE. 1999. Comparisons of the mutations in hprt exon 3 of T-lymphocytes from B6C3F1 mice and F344 rats exposures by inhalation to 1,3-butadiene or 1,2:3.4-diepoxybutane. Mutat Res 429:107-125.
41. Mirkes PE. Brown NA, Kajbaf M, Lamb JH, Farmer PB, Naylor S. 1992. Identification of cyclophosphamide - DNA adducts in rat embryos exposed in vitro to 4-hydroperoxycyclophosphamide. Chem Res Toxicol 5:382-385.
42. Mirsalis JC, Monforte JA, Winegar RA. 1994. Transgenic animal models for measuring mutations in vivo. Crit Rev Toxicol 24: 255-280.
43. Moriya M, Zhang W, Johnson F, Grollman AP. 1994. Mutagenic potency of exocyclic DNA adducts: marked differences between Escherichia coli and simian kidney cells. Proc Natl Acad Sci U S A 91:11899-11903.
44. Myhr BC. 1991. Validation studies with Muta™ Mouse: A transgenic mouse model for detecting mutations in vivo. Environ Mol Mutagen 18:308-315.
45. Nishino H, Schaid DJ, Buettner VL, Haavik J, Sommer SS. 1996. Mutation frequencies but not mutant frequencies in Big Blue® mice fit a poisson distribution. Environ Mol Mutagen 28:414-417.
46. Patel JM. 1990. Metabolism and pulmonary toxicity of cyclophosphamide. Pharmacol Ther 47:137-146.
47. Provost GS, Short JM. 1994. Characterization of mutations induced by ethylnitrosourea in seminiferous tubule germ cells of transgenic B6C3F1 mice. Proc Natl Acad Sci U S A 91:6564-6568.
48. Provost GS, Mirsalis JC, Rogers BJ, Short JM. 1996. Mutagenic response to benzene and tris(2,3-dibromopropyl)-phosphate in the lamdba lacl transgenic mouse mutation assay: A standardized approach to in vivo mutation analysis. Environ Mol Mutagen 28:342-347.
49. Shelby MD, Erexson GL, Hook GJ, Tice RR. 1993. Evaluation of a three-exposure mouse bone marrow micronucleus protocol: results with 49 chemicals. Environ Mol Mutagen 21:160-179.
50. Skopek TR. 1995. Of mice and men: target size and sensitivity. Mutat Res 331:225-228.
51. Skopek TR, Walker VE, Cochrane JE, Craft TR, Cariello NF. 1992. Mutational spectrum at the Hprt locus in splenic T cells of B6C3F1 mice exposed to N-ethyl-N-nitrosourea. Proc Natl Acad Sci U S A 89:7866-7870.
52. Smith RA, Williamson DS, Cohen SM. 1989. Identification of 3,N4-propanodeoxycytidine 5′-monophosphate formed by reaction of acrolein with deoxycytidine-5′-monophosphate. Chem Res Toxicol 2:267-271.
53. Smith RA, Williamson DS, Cerny RL, Cohen SM. 1990. Detection of 1,N6-propanodeoxyadenosine in acrolein-modified polydeoxyadenylic acid and DNA by 32P-postlabeling. Cancer Res 50:3005-3012.
54. Smith RD, Kehrer JP. 1991. Cooxidation of cyclophosphamide as an alternative pathway for its bioactivation and lung toxicity. Cancer Res 51:542-548.
55. Sodum RS, Shapiro R. 1988. Reaction of acrolein with cytosine and adenine derivatives. Bioorg Chem 16:272-282.
56. Suzuki T, Hayashi M, Ochiai M, Wakabayashi K, Ushijima T, Sugimura T, Nagao M, Sofuni T. 1996a. Organ variation in the mutagenicity of MeIQ in Big Blue lacl transgenic mice. Mutat Res 369:45-49.
57. Suzuki T. Itoh T, Hayashi M, Nishikawa Y, Ikezaki S, Furukawa F, Takahashi M, Sofuni T. 1996b. Organ variation in the mutagenicity of dimethylnitrosamine in Big Blue® mice. Environ Mol Mutagen 28:348-353.
58. Tao KS, Urlando C, Heddle JA. 1993. Comparison of somatic mutation in a transgenic versus host locus. Proc Natl Acad Sci U S A 90:10681-10685.
59. U.S. Environmental Protection Agency (US EPA). 1996. Proposed guidelines for carcinogen risk assessment. EPA/600/P-92/003C. Washington: US Environmental Protection Agency.
60. Ushijima T, Hosoya Y, Ochiai M, Kushida H, Wakabayashi K, Suzuki T, Hayashi M, Sofuni T, Sugimura T, Nagao M. 1994. Tissue-specific mutational spectra of 2-amino-3.4-dimethylimidazo[4.5-f]quinoline in the liver and bone marrow of lacI transgenic mice. Carcinogenesis 15:2805-2809.
61. Vu TV, Fenselau C, Colvin OM. 1981. Identification of three alkylated nucleotide adducts from the reaction of guanosine-5′-monophosphate with phosphoramide mustard. J Am Chem Soc 103:7362-7364.
62. Walker VE, Skopek TR. 1993. A mouse model for the study of in vivo mutational spectra: Sequence specificity of ethylene oxide at the hprt locus. Mutat Res 288:151-162.
63. Walker VE, Gorelick NJ, Andrews JL, Craft TR, de Boer JG, Glickman BW, Skopek TR. 1996. Frequency and spectrum of ethylnitrosourea induced mutation at the hprt and lacl loci in splenic T-cells of exposed lacl transgenic mice. Cancer Res 56:4654-4661.
64. Walker VE, Andrews JL, Upton PB, de Boer JG, Gorelick NJ. 1999. Detection of cyclophosphamide-induced mutations at the hprt but not the lacI locus in splenic T-cells of exposed transgenic mice. Environ Mol Mutagen 34:167-181.
65. Walker VE, Meng Q, Clement CL. 1997. Spectra of mutations in HPRT exon 3 of T-cells from F344 rats and lad transgenic and nontransgenic B6C3F1 mice exposed by inhalation to ethylene oxide. Environ Mol Mutagen 29(Suppl. 28):54.
66. Winegar RA, Lutze LH, Hamer JD, O'Loughlin KG, Mirsalis JC. 1994. Radiation-induced point mutations, deletions and micronuclei in lacl transgenic mice. Mutat Res 307:479-487.
67. Yamada H, Kaneko H, Takeuchi K, Oguri K, Yoshimura H. 1992. Tissue-specific expression, induction and inhibition through metabolic intermediate-complex formation of guinea pig cytochrome P450 belonging to the CYP2B subfamily. Arch Biochem Biophys 299: 248-254.